EVALUATION OF THE EFFECTIVENESS OF ALLERGEN-SPECIFIC IMMUNOTHERAPY IN PATIENTS WITH POLLINOSIS.

Abstract

Pollinosis is a common IgE-mediated allergic disease caused by sensitization to pollen allergens and is characterized by seasonal nasal, ocular, and respiratory symptoms that significantly impair patients’ quality of life. The disease often leads to decreased work productivity, sleep disturbances, and psychological discomfort, and may be associated with comorbid conditions such as allergic rhinitis, conjunctivitis, and bronchial asthma. Allergen-specific immunotherapy (ASIT) is currently considered the only etiopathogenetic treatment capable of modifying the natural course of allergic diseases. Unlike symptomatic therapy, ASIT directly influences the underlying immunological mechanisms of allergy by inducing immune tolerance to causative allergens, resulting in long-term clinical benefits.